Progress in Personalized Medicine Is Slower Than Some Had Expected, Partly Because of the Science and Partly Because of Insufficient Economic Incentives, Particularly for Investing in Molecular Diagnostics (MDX)

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.083
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV


Related search